Please note: AABB reserves the right to make updates to this program.
Live Program Date: Wednesday, July 10, 2019 - On-Demand Available
Master Program Number: 19EL-450 (see program format numbers below under Registration)
After participating in this educational activity, participants should be able to:
Platelet transfusion refractoriness is an increasing issue in heavily transfused patients such as patients with hematologic malignancies. The blood bank and HLA laboratory play an important role in assessing clinical refractoriness and helping clinicians determine whether there is an immune or non-immune etiology (or both). Dr. Peña will describe his institution’s approach to the platelet refractory patient.
|Single Viewer: On-Demand||Register||19EL-450-4035|
|Group Viewing: On-Demand||Register||19EL-450-8035|
AABB designates both the live and on-demand version of this eCast each eligible for 1 continuing education credits/contact hours for Physicians, General Participation, California Nurse, California Lab Personnel and Florida Lab Personnel. The number and type of credits awarded for this program (both live and on-demand) was determined by the program duration. For more information on each credit type please visit our Continuing Education Credits webpage.
Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.
Dr. Ryan Peña received his PhD, MD from Baylor College of Medicine. He completed residency in Clinical Pathology and training in Histocompatibility and Immunogenetics at the Massachusetts General Hospital and fellowship training at the Harvard Medical School Joint Program in Transfusion Medicine. He currently serves as the Director of the HLA Laboratory at Beth Israel Deaconess Medical Center. His interests include studying the pathomechanisms of HLA antibodies and optimizing transfusion support of patients with HLA alloimmune platelet refractoriness.